LENZ Therapeutics, Inc. (NASDAQ: LENZ) is a Healthcare company (Biotechnology) with a market capitalization of $110M. The Maz Rating grades it against the other companies in its sector.
LENZ Therapeutics, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $3.50, LENZ Therapeutics, Inc. trades at 8.7x sales and 0.6x book value. Over the last twelve months it generated about $13M of revenue and a net loss of $144M. It runs a gross margin of 80.2%, an operating margin of -1211.2% and a net margin of -1135.0%. It shows return on equity of -59.6%, return on invested capital of -77.8% and a free cash flow yield of -116.1%. On the balance sheet: a debt-to-equity ratio of 0.00 and a current ratio of 11.66. Over the past 52 weeks the share price ranged from $2.80 to $32.13, with a beta of 1.81.
LENZ Therapeutics, Inc. does not currently pay a dividend.
6 Wall Street analyst ratings cover the stock: 5 Buy and 1 Hold, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
LENZ Therapeutics, Inc. is a biopharmaceutical firm whose primary mission involves the advancement and commercialization of new treatments designed to enhance vision for individuals in the United States. The company's portfolio features two investigational products, LNZ100 and LNZ101, both of which are currently undergoing late-stage Phase III clinical trials as potential solutions for presbyopia. Corporate operations for LENZ Therapeutics are situated in Del Mar, California.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
No. As of September 2026, LENZ Therapeutics, Inc. (LENZ) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 0.00% / 30% · (Cash+Inv) / Mkt Cap (36m) 155.3% / 30% · Interest income / Revenue 58.7% / 5% | Fail |
| S&P Global | Debt / Mkt Cap (36m) 0.00% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 155.3% / 33% · Receivables / Mkt Cap (36m) 0.72% / 49% · Interest income / Revenue 58.7% / 5% | Fail |
| Dow Jones | Debt / Mkt Cap (24m) 0.00% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 155.3% / 33.33% · Receivables / Mkt Cap (24m) 0.72% / 33.33% · Interest income / Revenue 58.7% / 5% | Fail |
| MSCI | Debt / Avg Assets (4Q) 0.00% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 94.5% / 33.33% · Receivables / Avg Assets (4Q) 0.20% / 33.33% · Interest income / Revenue 58.7% / 5% | Fail |
| FTSE | Debt / Total Assets 0.00% / 33.33% · (Cash+ST Inv) / Total Assets 94.1% / 33.33% · (Cash+Recv) / Total Assets 94.5% / 33.33% · Interest income / Revenue 58.7% / 5% | Fail |
No. As of September 2026, LENZ Therapeutics, Inc. (LENZ) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
No. LENZ Therapeutics, Inc. is over the AAOIFI limit on (Cash+Inv) / Mkt Cap (36m) and Interest income / Revenue.
About 58.7% of each dividend: LENZ Therapeutics, Inc.'s interest income as a share of its revenue. Give that share to charity; the dividend purification calculator works it out per holding.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.